schemaVersion:

1-K: Filer Information

Issuer CIK
0001700800 
Issuer CCC
XXXXXXXX 
Is filer a shell company? Radio button not checked Yes Radio button checked No
Is the electronic copy of an official filing submitted in paper format? Checkbox not checked
File Number
 
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? Radio button not checked Yes Radio button checked No
Successor File Number
 

Submission Contact Information

Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
Would you like a Return Copy? Checkbox not checked
Period
12-31-2017 
Name
 
Phone
 
E-Mail Address
 
Notify via Filing Website only? Checkbox not checked

1-K: Tab 1 Notification

This Form 1-K is to provide an Radio button not checked Annual Report Radio button checked Special Financial Report for the fiscal year
Fiscal Year End

12-31-2017 

Exact name of issuer as specified in the issuer's charter

EMERALD HEALTH PHARMACEUTICALS INC. 

CIK

0001700800 

Jurisdiction of Incorporation / Organization

DELAWARE  

I.R.S. Employer Identification Number

82-0669961 

Address of Principal Executive Offices

Address 1

5910 PACIFIC CENTER BLVD. 

Address 2

SUITE 300 

City

SAN DIEGO 

State/Country

CALIFORNIA  

Mailing Zip/ Postal Code

92121 

Phone

858-352-0622 

Title of each class of securities issued pursuant to Regulation A

Common Stock 

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Checkbox not checkedThe following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement

024-10810 

Date of qualification of the offering statement

03-29-2018 

Date of commencement of the offering

03-29-2018 

Amount of securities qualified to be sold in the offering

10000000 

Amount of securities sold in the offering

0 

Price per security

$ 5.0000 

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 50000000.00 

The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders

$ 0.00 

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider
N/A
Underwriters - Fees
$ 0.00 
Sales Commissions - Name of Service Provider
N/A
Sales Commissions - Fee
$ 0.00 
Finders' Fees - Name of Service Provider
N/A
Finders' Fees - Fees
$ 0.00 
Accounting or Audit - Name of Service Provider
Deloitte & Touche LLP
Accounting or Audit - Fees
$ 55000.00 
Legal - Name of Service Provider
Morrison & Foerster LLP
Legal - Fees
$ 135000.00 
Promoters - Name of Service Provider
N/A
Promoters - Fees
$ 0.00 
Blue Sky Compliance - Name of Service Provider
N/A
Blue Sky Compliance - Fees
$ 0.00 
CRD Number of any broker or dealer listed

 

Net proceeds to the issuer

$ 49750000.00 

Clarification of responses (if necessary)

The expected fees in connection with this offering total $250,000. The expected fees include the $190,000 listed above as well as an additional $60,000 for other associated fees.